Ocular Therapeutix (0OT) Stock Statistics & Valuation Metrics
Total Valuation
Ocular Therapeutix has a market cap or net worth of EUR 1.37B. The enterprise value is EUR 1.69B.
- Market Cap
- EUR 1.37B
- Enterprise Value
- EUR 1.69B
Share Statistics
Ocular Therapeutix has 219,615,880 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 219,615,880
- Owned by Insiders
- 2.72%
- Owned by Institutions
- 36.68%
Financial Efficiency
Ocular Therapeutix’s return on equity (ROE) is -0.41 and return on invested capital (ROIC) is -35.53%.
- Return on Equity (ROE)
- -0.41
- Return on Assets (ROA)
- -0.33
- Return on Invested Capital (ROIC)
- -35.53%
- Return on Capital Employed (ROCE)
- -0.36
- Revenue Per Employee
- 159.46K
- Profits Per Employee
- -818.27K
- Employee Count
- 325
- Asset Turnover
- 0.06
- Inventory Turnover
- 1.84
Valuation Ratios
The current PE Ratio of Ocular Therapeutix is -4.91. Ocular Therapeutix’s PEG ratio is 0.43.
- PE Ratio
- -4.91
- PS Ratio
- 29.41
- PB Ratio
- 3.01
- Price to FCF
- -6.00
- Price to Operating Cash Flow
- -6.58
- PEG Ratio
- 0.43
Income Statement
In the last 12 months, Ocular Therapeutix had revenue of 51.82M and earned -265.94M in profits. Earnings per share was -1.42.
- Revenue
- 51.82M
- Gross Profit
- 45.25M
- Operating Income
- -270.02M
- Pretax Income
- -265.94M
- Net Income
- -265.94M
- EBITDA
- -249.78M
- Earnings Per Share (EPS)
- -1.42
Cash Flow
In the last 12 months, operating cash flow was -238.24M and capital expenditures -16.86M, giving a free cash flow of -255.10M billion.
- Operating Cash Flow
- -238.24M
- Free Cash Flow
- -255.10M
- Free Cash Flow per Share
- -1.13
Dividends & Yields
Ocular Therapeutix pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -16.67%
- Earnings Yield
- -19.23%
Stock Price Statistics
- Beta
- 0.56
- 52-Week Price Change
- -36.78%
- 50-Day Moving Average
- 7.71
- 200-Day Moving Average
- 7.72
- Relative Strength Index (RSI)
- 46.56
- Average Volume (3m)
- 1,185
Important Dates
Ocular Therapeutix upcoming earnings date is Nov 09, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 03, 2026
- Next Earnings Date
- Nov 09, 2026
- Ex-Dividend Date
- ―
Financial Position
Ocular Therapeutix as a current ratio of 15.39, with Debt / Equity ratio of 12.19%
- Current Ratio
- 15.39
- Quick Ratio
- 15.32
- Debt to Market Cap
- 0.03
- Net Debt to EBITDA
- 2.63
- Interest Coverage Ratio
- -22.82
Taxes
In the past 12 months, Ocular Therapeutix has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Ocular Therapeutix EV to EBITDA ratio is -3.55, with an EV/FCF ratio of -3.96.
- EV to Sales
- 19.43
- EV to EBITDA
- -3.55
- EV to Free Cash Flow
- -3.96
- EV to Operating Cash Flow
- -4.25
Balance Sheet
Ocular Therapeutix has EUR 598.64M in cash and marketable securities with EUR 79.38M in debt, giving a net cash position of EUR 519.26M billion.
- Cash & Marketable Securities
- EUR 598.64M
- Total Debt
- EUR 79.38M
- Net Cash
- EUR 519.26M
- Net Cash Per Share
- EUR 2.36
- Tangible Book Value Per Share
- EUR 2.31
Margins
Gross margin is 87.11%, with operating margin of -603.04%, and net profit margin of -579.10%.
- Gross Margin
- 87.11%
- Operating Margin
- -603.04%
- Pretax Margin
- -579.10%
- Net Profit Margin
- -579.10%
- EBITDA Margin
- -546.73%
- EBIT Margin
- -557.20%
Analyst Forecast
The average price target for Ocular Therapeutix is EUR 21.60, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- EUR 21.60
- Price Target Upside
- 240.09% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 9
- Revenue Growth Forecast
- -14.32%
- EPS Growth Forecast
- -3.11%
Scores
- Smart Score
- 7
- AI Score
- ―